At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 1 enrolled
Drug / intervention
Mavrilimumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
In Brief
A Phase 2 clinical trial evaluating Mavrilimumab and Placebo for COVID 19 and 2 related conditions. Completed, enrolled 1 participant across 1 site.
Detailed Summary
The purpose of this prospective, Phase 2, multicenter, blinded, randomized placebo controlled study is to demonstrate that early treatment with mavrilimumab prevents progression of respiratory failure in patients with severe COVID-19 pneumonia and clinical and biological features of hyper-inflammation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID 19, SARS-CoV 2, Pneumonia
CountriesUnited States
CollaboratorsKiniksa Pharmaceuticals, Ltd.
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartMay 2020
First PostedJul 2020
Primary CompletionNov 2020
TodayJul 2026
First PostedJul 30, 2020
Enrollment StartMay 20, 2020
Primary CompletionNov 16, 2020
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 5.9 years ago
Interventions
Mavrilimumabdrug
Treatment infusion
Placebodrug
Placebo infusion